SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) on Oct. 5, 2026, regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market. To view the full press release, visit https://ibn.fm/A6dJ8.
The FDA submission is a critical step for SS Innovations as it seeks to enter the highly competitive U.S. surgical robotics market, which is currently dominated by Intuitive Surgical's da Vinci system. The SSi Mantra is designed to be more affordable and accessible, potentially expanding robotic surgery to a larger segment of the global population. The company's vision is to make the benefits of robotic surgery affordable and accessible, and a successful U.S. launch could disrupt the market by offering a cost-effective alternative. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures, demonstrating its versatility. The system features 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and the ability to superimpose 3D models of diagnostic imaging. It also utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries. The optional SSi MantrAsana tele-surgeon console provides telesurgery capability, which could enable remote surgeries and improve access to care in underserved areas.
The implications of this announcement extend beyond SS Innovations. If the FDA grants clearance, it would mark the first U.S. approval for a surgical robotic system developed in India, highlighting the growing global competitiveness of Indian medical technology. It could also pressure existing players to reduce costs and innovate, ultimately benefiting patients and healthcare providers. The company's focus on affordability could lead to wider adoption of robotic surgery, which has been shown to reduce complications and recovery times compared to traditional open surgery. However, the U.S. market presents challenges, including regulatory hurdles, competition, and the need for extensive clinical evidence. The FDA's review will scrutinize the data from the bridging study and human factors validation to ensure the system meets U.S. safety and efficacy standards. SS Innovations is headquartered in India but is a U.S. company, and it has a comprehensive suite of SSi Mudra surgical instruments that support a variety of procedures including cardiac surgery. The company's website, ssinnovations.com, provides more information, and updates are also available on LinkedIn. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
TechMediaWire, a specialized communications platform, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, and provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. The platform also offers press release enhancement and social media distribution, among other corporate communications solutions. A full disclaimer is available at https://www.TechMediaWire.com/Disclaimer.
